Sigma-1 receptor antagonists: promising players in fighting neuropathic pain.
E-52862
MR309
PV-752
chemotherapy-induced peripheral neuropathy
neuropathic pain
postherpetic neuralgia
sigma-1 receptor antagonist
Journal
Pharmaceutical patent analyst
ISSN: 2046-8962
Titre abrégé: Pharm Pat Anal
Pays: England
ID NLM: 101582615
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
pubmed:
17
6
2020
medline:
27
4
2021
entrez:
17
6
2020
Statut:
ppublish
Résumé
Sigma-1 receptors (S1Rs) are strongly correlated to neuropathic pain (NP), since their inactivation may decrease allodynia or dysesthesia, promoting analgesic effects. In the recent patent landscape, S1R antagonists endowed with nanomolar S1Rs affinity emerged as potent antinociceptive agents. So far, three patented compounds have been proposed for counteracting NP. Particularly
Identifiants
pubmed: 32539668
doi: 10.4155/ppa-2020-0007
doi:
Substances chimiques
Analgesics, Opioid
0
Narcotic Antagonists
0
Receptors, sigma
0
Tramadol
39J1LGJ30J
Nortriptyline
BL03SY4LXB
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM